Transplantation And Cellular Therapy

SCI SCIE

国际简称：BIOL BLOOD MARROW TR 参考译名：移植和细胞治疗

主要研究方向：Medicine-Hematology 非预警期刊

《移植和细胞治疗》(Transplantation And Cellular Therapy)是一本由Elsevier出版的以Medicine-Hematology为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

2区中科院分区
Q1 JCR分区
217 年发文量
4.7 IF影响因子
开放是否OA
None 出版语言

Transplantation and Cellular Therapy, the official publication of the American Society for Transplantation and Cellular Therapy , focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation and the growing field of transplant and non-transplant cellular immunotherapies. The Journal publishes original research reports, practice guidelines, reviews, editorials, commentaries, and letters to the editor.This magazine is committed to promoting the development of scientific research and clinical applications in the fields of cell therapy and transplantation, providing a platform for scientists, doctors, and researchers engaged in related research worldwide to exchange and share the latest research results. As a professional journal focusing on the fields of cell therapy and transplantation, it provides a platform for researchers to showcase their research results and exchange academic views, which is of great significance for promoting the development of related fields.

[ 查看全部 ]

投稿咨询加急咨询

Transplantation And Cellular Therapy期刊信息

ISSN：2666-6375
出版语言：None
是否OA：开放
E-ISSN：2666-6367
出版地区：UNITED STATES
是否预警：否
出版商：Elsevier
开源占比：0.1987
Gold OA文章占比：28.92%
OA被引用占比：
出版国人文章占比：0
出版撤稿占比：
研究类文章占比：89.86%

Transplantation And Cellular Therapy CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

8.1

2.251

1.32

学科类别	分区	排名	百分位
大类：Medicine 小类：Transplantation	Q1	6 / 55	90%
大类：Medicine 小类：Hematology	Q1	20 / 151	87%
大类：Medicine 小类：Immunology and Allergy	Q1	50 / 234	78%
大类：Medicine 小类：Molecular Medicine	Q2	50 / 179	72%
大类：Medicine 小类：Cell Biology	Q2	85 / 289	70%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Transplantation And Cellular Therapy中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	HEMATOLOGY 血液学 IMMUNOLOGY 免疫学 TRANSPLANTATION 移植	2区 3区 2区

Transplantation And Cellular Therapy JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：HEMATOLOGY	SCIE	Q1	20 / 103	81.1
学科：IMMUNOLOGY	SCIE	Q2	57 / 183	69.1
学科：TRANSPLANTATION	SCIE	Q1	6 / 30	81.7
学科：HEMATOLOGY	SCIE	Q1	16 / 103	84.95
学科：IMMUNOLOGY	SCIE	Q1	34 / 183	81.69
学科：TRANSPLANTATION	SCIE	Q1	7 / 30	78.33

Transplantation And Cellular Therapy历年数据统计

影响因子

中科院分区

Transplantation And Cellular Therapy中国学者发文选摘

1、Exploration of In Vivo T-cell Depletion protocols in Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancie
Author: Chen, Hongru; Zhang, Yi; Fan, Yamin; Liu, Qianlin; Min, Wenyu; Xia, Linghui; Shi, Wei

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 4, pp. 412-427. DOI: 10.1016/j.jtct.2025.10.038
2、Prophylactic Versus Preemptive Donor Lymphocyte Infusion in Refractory/Relapsed AML Post-Allogeneic Transplant: A Retrospective Comparative Stud
Author: Wu, Ning; Yan, Chen-hua; Kong, Jun; Lv, Meng; Mo, Xiao-Dong; Sun, Yu-Qian; Cheng, Yi-Fei; Xu, Lan-Ping; Zhang, Xiao-Hui; Huang, Xiao-Jun; Wang, Yu

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 3, pp. 3020-. DOI: 10.1016/j.jtct.2025.10.029
3、Propensity Score-Matched Analysis Supports the Survival Benefits of Combination Chimeric Antigen Receptor T-Cell Therapy with Autologous Transplantation in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Insights from a Real-World Study in Chin
Author: Sheng, Kaiyu; You, Tao; Zhou, Jin; Wang, Yun; Wu, Depei; Huang, Haiwen

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 3, pp. 2880-. DOI: 10.1016/j.jtct.2025.11.001
4、One-Year Tear Proteomic Alterations with Topical Cyclosporine-A 0.1% Emulsion in Patients with Allogeneic Stem Cell Transplan
Author: Liu, Chang; Wang, Xinyue; Yeo, Sharon Wan Jie; Lee, Isabelle Xin Yu; Linn, Yeh Ching; Ho, Aloysius; Than, Hein; Quek, Jeffrey Kim Siang; Hwang, William Ying Khee; Lim, Francesca Lorraine Wei Inng; Zhou, Lei; Liu, Yu-Chi; Tong, Louis; Lim, Li

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 3, pp. 3040-. DOI: 10.1016/j.jtct.2025.11.017
5、Impact of HLA Alloimmunization on Availability of HLA Matched and Mismatched Unrelated Allogeneic Hematopoietic Cell Donors for Transplantation Disproportionately Impacts Female Patient
Author: Shaffer, Brian C.; Blouin, Amanda G.; Rapoport, Candice; Wells, Deborah S.; Chinapen, Stephanie; Perales, Miguel-Angel; Devine, Steven M.; Auletta, Jeffery J.; Stefanski, Heather E.; Spellman, Stephen R.; Maiers, Martin

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 2, pp. -. DOI:
6、Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed By Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind phase 3 Study (HOVON 181 AML / AMLSG 37-25
Author: Raaijmakers, Marc; Dohner, Hartmut; Breems, Dimitri; Byrd, John C.; Dohner, Konstanze; Esteve, Jordi; Gjertsen, Bjorn Tore; Gradowska, Patrycja; Huls, Gerwin; Kaare, Ain; Kim, Hee-Je; Kiyoi, Hitoshi; Kontro, Mika; Krawczyk, Janusz; Lazarevic, Vladimir; Lenartova, Andrea; Mims, Alice; Refos, Jeannine M.; Rollig, Christoph; Schrade, Anika; Sikorska, Karolina; Theocharides, Alexandre; Valk, Peter; Venditti, Adriano; Wang, Jianxiang; Wei, Andrew H.; Wierzbowska, Agnieszka; Andrius-Zucenka; Ferrante, Lucille; Guttke, Christina; Langlois, Angelique; Loefgren, Christina; Packman, Kathryn; Shastri, Prathap Nagaraja; Schuier, Natasha; Thayu, Meena; Trancucci, Danielle; Lowenberg, Bob; Bullinger, Lars

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 2, pp. -. DOI:
7、Camelot-2: A phase 3 Randomized, Double-Blind, Placebo-Controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A rearrangements or NPM1 mutations, Who Are Ineligible for Intensive Chemotherap
Author: Jabbour, Elias; Sallman, David A.; Briseno-Toomey, Deborah; Guttke, Christina; Huang, Xiaojun; Dillon, Richard; Ferrante, Lucille; Ikesoe, Takayuki; Langlois, Angelique; Loefgren, Christina; Nachmias, Boaz; Nelson, Ayelet; Packman, Kathryn; Shastri, Prathap Nagaraja; Recher, Christian; Roboz, Gail J.; Schuier, Natasha; Thayu, Meena; Trancucci, Danielle; Zuppa, Athena; Ro, Christoph; Wei, Andrew H

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 2, pp. -. DOI:
8、Long-Term Progression-Free Survival Benefit with Ciltacabtagene Autoleucel in Standard-Risk relapsed/refractory Multiple Myelom
Author: Costa, Luciano J.; Oriol, Albert; Dytfeld, Dominik; Manier, Salomon; Voorhees, Peter M.; Lin, Yi; Htut, Myo; Roeloffzen, Wilfried; Ho, Phoebe Joy; Shah, Urvi A.; Zhao, Man; Li, Quanlin; Balogh, Agnes; Li, Katherine; Slaughter, Ana; Benachour, Nina; Lonardi, Carolina; Ghosh, Arnab; Sun, Huabin; Lendvai, Nikoletta; Lengil, Tamar; Patel, Nitin; Koneru, Mythili; Florendo, Erika; Filho, Octavio Costa; Mahajan, Vrinda; Rodriguez-Otero, Paula; Strouse, Christopher; Stewart, A. Keith; Sidana, Surbhi

Journal: TRANSPLANTATION AND CELLULAR THERAPY. 2026; Vol. 32, Issue 2, pp. -. DOI: